topotecan

The agonist combines cRGD peptide-targeted polydopamine-coated zeolitic imidazolate framework-8 with the photosensitizer indocyanine green and the chemotherapeutic drug topotecan...The mild photothermal therapy-induced immunogenic cell death promotes the initiation of antitumor immunity, while also enhancing the effectiveness of immune checkpoint blockade. In vivo studies show that cDZ@IP significantly inhibits primary and distant tumor growth and prevents lung metastasis, providing a promising strategy for STING pathway-targeted cancer immunotherapy.

P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026

P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=406, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting

P3, N=438, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting

Drug sensitivity analysis revealed that high CLIP2 expression conferred resistance to platinum-based agents, topotecan, and gemcitabine, but heightened sensitivity to olaparib, cediranib, and pictilisib. Through bioinformatic analysis, this study proposes CLIP2 as a potential biomarker associated with platinum resistance and immune microenvironment patterns in ovarian cancer. These preliminary findings provide a basis for subsequent mechanistic studies and larger validation cohorts to confirm its clinical relevance in guiding immunotherapy and targeted treatment approaches.

Convection-enhanced delivery of topotecan enables sustained local chemotherapy for recurrent glioblastoma and was associated with reduced tumor proliferation in our previous phase 1B clinical trial...By integrating paired clinical biopsies with time-resolved and mechanistic experimental models, this study provides a framework for understanding how local chemotherapy reshapes the glioblastoma microenvironment and for future studies evaluating dose, schedule, treatment duration, and combination strategies. These findings demonstrate that paired, spatially annotated tissue sampling from small, precisely characterized clinical cohorts can yield mechanistic insight that conventional radiographic and survival endpoints cannot provide, and support tissue-based response assessment as the appropriate paradigm for evaluating novel locoregional therapies in glioblastoma.

Finally, drug sensitivity profiling and experimental validation suggested that NUDT1 levels may predict response to topoisomerase inhibitors, such as Topotecan and Irinotecan. In conclusion, NUDT1 is a key oncogenic factor involved in redox homeostasis and is closely associated with the immune microenvironment in OS, representing a potential prognostic biomarker and therapeutic target.

P3, N=82, Not yet recruiting, Genmab

P3, N=404, Active, not recruiting, Biotheus Inc. | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, Targeted Therapy Technologies, LLC | Trial completion date: Nov 2028 --> Dec 2029 | Trial primary completion date: Nov 2028 --> Nov 2029

P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027